Submitted by Anonymous (not verified) on 4 March 2025 - 13:45
Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, Nivolumab,Relatlimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0458/2023
Source: